Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 0.65
(-5.8%)
SEK 0.65
(-5.8%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 42.63 Million SEK | -6.36% |
| 2022 | 47.32 Million SEK | -5.63% |
| 2021 | 50.14 Million SEK | 13.7% |
| 2020 | 44.1 Million SEK | -3.68% |
| 2019 | 45.78 Million SEK | 16.58% |
| 2018 | 39.27 Million SEK | 25.46% |
| 2017 | 31.3 Million SEK | 14.74% |
| 2016 | 27.28 Million SEK | 18.3% |
| 2015 | 23.06 Million SEK | 85.64% |
| 2014 | 12.42 Million SEK | 24.9% |
| 2013 | 9.94 Million SEK | 10.68% |
| 2012 | 8.98 Million SEK | 155.74% |
| 2011 | 3.51 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 14.71 Million SEK | 1.38% |
| 2024 Q3 | - SEK | -94.06% |
| 2024 Q1 | 14.51 Million SEK | 2.13% |
| 2023 Q2 | 10.59 Million SEK | 4.42% |
| 2023 Q3 | 9.37 Million SEK | -11.54% |
| 2023 Q1 | 10.14 Million SEK | -9.1% |
| 2023 Q4 | 14.2 Million SEK | 51.62% |
| 2023 FY | 44.31 Million SEK | -6.36% |
| 2022 FY | 47.32 Million SEK | -5.63% |
| 2022 Q3 | 10.14 Million SEK | -31.51% |
| 2022 Q2 | 14.8 Million SEK | 32.06% |
| 2022 Q4 | 11.16 Million SEK | 10.05% |
| 2022 Q1 | 11.21 Million SEK | -12.35% |
| 2021 FY | 50.14 Million SEK | 13.7% |
| 2021 Q4 | 12.79 Million SEK | -2.08% |
| 2021 Q3 | 13.06 Million SEK | 0.63% |
| 2021 Q2 | 12.98 Million SEK | 14.83% |
| 2021 Q1 | 11.3 Million SEK | -5.59% |
| 2020 Q1 | 11.96 Million SEK | -9.3% |
| 2020 FY | 44.1 Million SEK | -3.68% |
| 2020 Q4 | 11.97 Million SEK | 41.83% |
| 2020 Q2 | 11.7 Million SEK | -2.18% |
| 2020 Q3 | 8.44 Million SEK | -27.88% |
| 2019 Q3 | 10.55 Million SEK | -14.04% |
| 2019 FY | 45.78 Million SEK | 16.58% |
| 2019 Q4 | 13.19 Million SEK | 24.98% |
| 2019 Q2 | 12.28 Million SEK | 25.97% |
| 2019 Q1 | 9.75 Million SEK | -8.41% |
| 2018 Q4 | 10.64 Million SEK | 11.0% |
| 2018 FY | 39.27 Million SEK | 25.46% |
| 2018 Q3 | 9.59 Million SEK | 0.32% |
| 2018 Q2 | 9.56 Million SEK | 0.87% |
| 2018 Q1 | 9.47 Million SEK | 16.28% |
| 2017 Q1 | 7.62 Million SEK | 158.84% |
| 2017 Q2 | 8.08 Million SEK | 6.02% |
| 2017 Q3 | 7.43 Million SEK | -8.02% |
| 2017 Q4 | 8.15 Million SEK | 9.57% |
| 2017 FY | 31.3 Million SEK | 14.74% |
| 2016 Q2 | 10.48 Million SEK | 78.52% |
| 2016 FY | 27.28 Million SEK | 18.3% |
| 2016 Q4 | 2.94 Million SEK | -63.06% |
| 2016 Q3 | 7.97 Million SEK | -23.91% |
| 2016 Q1 | 5.87 Million SEK | -18.3% |
| 2015 FY | 23.06 Million SEK | 85.64% |
| 2015 Q4 | 7.18 Million SEK | 11.81% |
| 2015 Q3 | 6.43 Million SEK | 22.92% |
| 2015 Q2 | 5.23 Million SEK | 24.13% |
| 2015 Q1 | 4.21 Million SEK | 13.17% |
| 2014 Q4 | 3.72 Million SEK | 26.83% |
| 2014 FY | 12.42 Million SEK | 24.9% |
| 2014 Q1 | 2.76 Million SEK | 75.21% |
| 2014 Q2 | 2.58 Million SEK | -6.3% |
| 2014 Q3 | 2.93 Million SEK | 13.4% |
| 2013 Q3 | 2.23 Million SEK | -27.47% |
| 2013 Q2 | 3.07 Million SEK | 0.0% |
| 2013 Q4 | 1.57 Million SEK | -29.35% |
| 2013 FY | 9.94 Million SEK | 10.68% |
| 2013 Q1 | 3.07 Million SEK | 0.0% |
| 2012 FY | 8.98 Million SEK | 155.74% |
| 2011 FY | 3.51 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.185% |
| Camurus AB (publ) | 1.05 Billion SEK | 95.977% |
| Mendus AB (publ) | 129.13 Million SEK | 66.987% |
| Lipum AB (publ) | 37.3 Million SEK | -14.273% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7501.145% |
| Simris Alg AB (publ) | 38.64 Million SEK | -10.326% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -50.503% |
| Active Biotech AB (publ) | 44.8 Million SEK | 4.858% |
| Amniotics AB (publ) | 29.07 Million SEK | -46.643% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -190.944% |
| BioArctic AB (publ) | 89.62 Million SEK | 52.434% |
| Cantargia AB (publ) | 290.01 Million SEK | 85.3% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -94.711% |
| CombiGene AB (publ) | 44.14 Million SEK | 3.425% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 70.185% |
| Genovis AB (publ.) | 88.19 Million SEK | 51.663% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 62.952% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -486.571% |
| Intervacc AB (publ) | 79.78 Million SEK | 46.566% |
| Kancera AB (publ) | 63.07 Million SEK | 32.413% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -672.459% |
| LIDDS AB (publ) | 27.75 Million SEK | -53.618% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -487.703% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 68.633% |
| OncoZenge AB (publ) | 15.9 Million SEK | -168.041% |
| Saniona AB (publ) | 1.07 Million SEK | -3858.403% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 86.74% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 88.079% |
| Xintela AB (publ) | 57.31 Million SEK | 25.619% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 76.542% |
| Ziccum AB (publ) | 27.87 Million SEK | -52.923% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -159.935% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 86.117% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -141.09% |
| Corline Biomedical AB | 30.16 Million SEK | -41.315% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 26.536% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 48.741% |
| Aptahem AB (publ) | 10.01 Million SEK | -325.769% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 68.349% |
| Fluicell AB (publ) | 28.61 Million SEK | -48.974% |
| Biovica International AB (publ) | 133.72 Million SEK | 68.119% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -115.422% |
| AcouSort AB (publ) | 25.87 Million SEK | -64.755% |
| Abliva AB (publ) | 27.86 Million SEK | -52.989% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 77.968% |
| 2cureX AB (publ) | 36.51 Million SEK | -16.742% |
| I-Tech AB | 40.14 Million SEK | -6.187% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.04% |
| Cyxone AB (publ) | 28.21 Million SEK | -51.102% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 61.02% |
| Biosergen AB | 26.8 Million SEK | -59.021% |
| Nanologica AB (publ) | 69.88 Million SEK | 38.999% |
| SynAct Pharma AB | 224.49 Million SEK | 81.01% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 3.495% |
| BioInvent International AB (publ) | 441.4 Million SEK | 90.342% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -77.972% |
| Alzinova AB (publ) | 36.39 Million SEK | -17.134% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 85.286% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -442.649% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 61.563% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -190.014% |